The function of the Transgenic Core Facility is to provide the investigators with the ability to inactivate and/or modify genes in vivo and thus to expedite the pursuit of the goals of the Program Project. The construction of standard transgenic mice and the targeted inactivation of genes in embryonic stem cells and subsequent production of chimeric animals are technically sophisticated and labor intensive procedures. Furthermore they involve a substantial investment in equipment. Consequently, the work and equipment should not be duplicated in the several laboratories within the Program Project. The centralized Transgenic Core Facility proposed here will provide transgenic animals more efficiently and reliably. Projects 3 and 4 within the Program will generate transgenic mouse models with reconstituted CD40 signaling in CD40 -/- knock-out mice or with disrupted signaling elements in the CD40 signaling pathway in normal mice, The B cells from such animals will be used in Projects 1, 2 and 3 to assess their utility in therapeutic protocols designed to induce tolerance to engraftment. The following core functions are proposed: 1) centralized housing of embryo donors and recipients 2) culturing, transformation, and analysis of embryonic stem cells 3) harvesting, microinjection, and re-implantation of embryos 4) delivery, fostering, and weaning of potentially transgenic animals 5) screening for gene integration 6) breeding and maintenance 7) cryopreservation of embryos

Project Start
1999-01-11
Project End
1999-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Type
DUNS #
660735098
City
Worcester
State
MA
Country
United States
Zip Code
01655
Covassin, L; Laning, J; Abdi, R et al. (2011) Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2r?(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease. Clin Exp Immunol 166:269-80
de Vries, V C; Elgueta, R; Lee, D M et al. (2010) Mast cell protease 6 is required for allograft tolerance. Transplant Proc 42:2759-62
Brehm, Michael A; Bortell, Rita; Diiorio, Philip et al. (2010) Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2rgammanull Ins2Akita mice. Diabetes 59:2265-70
Jurczyk, Agata; Pino, Steven C; O'Sullivan-Murphy, Bryan et al. (2010) A novel role for the centrosomal protein, pericentrin, in regulation of insulin secretory vesicle docking in mouse pancreatic beta-cells. PLoS One 5:e11812
Brehm, Michael A; Shultz, Leonard D; Greiner, Dale L (2010) Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes 17:120-5
Racki, Waldemar J; Covassin, Laurence; Brehm, Michael et al. (2010) NOD-scid IL2rgamma(null) mouse model of human skin transplantation and allograft rejection. Transplantation 89:527-36
Brehm, Michael A; Cuthbert, Amy; Yang, Chaoxing et al. (2010) Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol 135:84-98
Mangada, Julie; Pearson, Todd; Brehm, Michael A et al. (2009) Idd loci synergize to prolong islet allograft survival induced by costimulation blockade in NOD mice. Diabetes 58:165-73
King, M A; Covassin, L; Brehm, M A et al. (2009) Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol 157:104-18
King, Marie; Pearson, Todd; Shultz, Leonard D et al. (2008) A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol 126:303-14

Showing the most recent 10 out of 48 publications